Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls

1. Abstract

The Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls (commonly known by its acronym, SARC-F) is a brief, clinician- and self-administered five-item screening tool designed to identify individuals at risk for sarcopenia and related adverse geriatric outcomes. Developed by Theodore K. Malmstrom and John E. Morley in 2013, the instrument operationalizes cardinal clinical manifestations of skeletal muscle failure: loss of gross muscle strength, impaired ambulation, lower-extremity transfer failure, stair-climbing limitation, and fall frequency. Each item is scored ordinally from 0 to 2, yielding a cumulative scale score ranging from 0 to 10, wherein a clinical cut-off score of 4 or higher indicates high risk for sarcopenia and warrants formal diagnostic evaluation involving muscle mass quantification and physical performance testing. Extensive psychometric evaluations across geriatric, community-dwelling, hospitalized, and oncological populations have established that while the SARC-F demonstrates moderate internal consistency (Cronbach’s α typically ranging between 0.65 and 0.81), it exhibits outstanding test-retest reliability (≥ 0.80) and a robust unidimensional or two-factor latent structure. Although its diagnostic sensitivity against international consensus operational criteria (such as EWGSOP2, AWGS 2019, and SDOC) is typically modest (20% to 50%), its high diagnostic specificity (frequently exceeding 85% to 95%) and profound negative predictive value render it an optimal public health and clinical triage mechanism. Critically, the instrument shows superior predictive validity for hard downstream endpoints, including incident frailty, emergency room visits, prolonged hospitalization, loss of activities of daily living (ADL) independence, and all-cause mortality, bridging psychological self-perception of functional capacity with biomarker-informed geriatric assessment.

2. Keywords

SARC-F, Sarcopenia screening, Muscle strength, Functional mobility, Geriatric assessment, Psychometrics, Fall risk, Frailty, Physical performance, Activities of daily living

3. Authors

The original SARC-F questionnaire was conceptualized and developed by:

• Theodore K. Malmstrom, Ph.D. — Department of Psychiatry and Behavioral Neuroscience and Division of Geriatric Medicine, Saint Louis University School of Medicine, St. Louis, Missouri, United States.
• John E. Morley, M.B., B.Ch. — Division of Geriatric Medicine, Saint Louis University School of Medicine, St. Louis, Missouri, United States.

Prominent international adaptation and validation researchers include:

• Marjolein Visser, Ph.D. — Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
• Laura A. Schaap, Ph.D. — Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands (developers of the validated Dutch language adaptation).
• Alfonso J. Cruz-Jentoft, M.D., Ph.D. — Servicio de Geriatría, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain (co-chair of the European Working Group on Sarcopenia in Older People [EWGSOP]).

4. Purpose

The primary clinical and research objective of the Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls scale is to provide a rapid, inexpensive, non-invasive, and standardized screening mechanism for identifying individuals experiencing progressive loss of skeletal muscle function and mass. Sarcopenia is officially recognized as a generalized and progressive skeletal muscle disorder under the International Classification of Diseases (ICD-10-CM code M62.84). Despite its profound association with loss of independence, institutionalization, and premature mortality, formal diagnostic algorithms requiring dual-energy X-ray absorptiometry (DXA), bioelectrical impedance analysis (BIA), or computed tomography (CT) are frequently inaccessible in primary care, home health, and low-resource settings.

The theoretical rationale behind the SARC-F is grounded in functional kinesiology and health-related self-efficacy: before objective muscle atrophy is formally quantified via radiologic imaging, individuals experience noticeable functional decrements during basic and instrumental activities of daily living that require lower-extremity power, mechanical leverage, and balance control. By quantifying self-reported difficulty across five physical tasks representing dynamic strength, stability, and biomechanical power, the SARC-F bridges biological tissue degradation and perceived disability. In clinical workflows, the tool serves as “Case Finding” (Step 1 of the EWGSOP2 and Asian Working Group for Sarcopenia [AWGS] diagnostic pathways), screening out low-risk populations while directing high-risk individuals toward targeted diagnostic confirmatory assessments (e.g., grip strength dynamometry, chair rise testing, and appendicular lean mass quantification) and early lifestyle or nutritional interventions.

5. Psychological Construct

The overarching construct quantified by the SARC-F is perceived functional limitation secondary to skeletal neuromuscular insufficiency. This construct operates at the intersection of psychomotor capability, physical vulnerability, and self-appraisal of motor competence. Rather than measuring isolated maximum isometric force output in laboratory isolation, the scale assesses the patient’s ecological performance across five interconnected physical dimensions:

• Strength (S): Assesses upper- and lower-body kinetic chain integrity via perceived load-bearing capacity (lifting and carrying 10 pounds / ~4.5 kg). Biomechanically, this evaluates shoulder girdle stability, grip strength, and core axial loading capacity. Psychologically, it reflects self-efficacy regarding common household manual handling tasks (e.g., carrying groceries).
• Assistance in Walking (A): Assesses basic functional ambulation across a level surface (crossing an ordinary room). This evaluates biomechanical gait velocity, single-leg stance equilibrium, proprioceptive motor control, and reliance on structural or human assistive devices.
• Rise from a Chair (R): Evaluates closed-kinetic-chain concentric power of the quadriceps femoris, gluteus maximus, and trunk stabilizers during sit-to-stand and bed-transfer motions. This dimension represents an indispensable milestone of homeostatic functional independence; loss of sit-to-stand ability heavily predicts institutionalization.
• Climb Stairs (C): Evaluates eccentric and concentric load tolerance, cardiopulmonary resilience, and unilateral knee extensor strength during ascending a flight of 10 stairs. This reflects advanced mobility and high-threshold motor unit recruitment.
• Falls (F): Captures episodic neuromotor failure, postural instability, and loss of balance corrective mechanisms over an extended temporal window (the past 12 months). Frequent falling represents a critical clinical manifestation of muscle weakness and vestibular/proprioceptive decompensation.

6. Theoretical Framework

The SARC-F is theoretically anchored in the Disablement Process Model developed by Verbrugge and Jette (1994) and the World Health Organization’s International Classification of Functioning, Disability and Health (ICF). Under the Disablement Process framework, human functional decline proceeds sequentially through four major domains: Pathology (e.g., motor neuron loss, muscle protein catabolism, chronic inflammation), Impairments (e.g., reduced maximum voluntary contraction, loss of Type II fast-twitch muscle fibers), Functional Limitations (e.g., difficulty climbing stairs, slow walking speed, inability to rise from seated positions), and Disability (e.g., inability to live independently or maintain social participation).

The SARC-F intentionally anchors its measurement layer directly at the Functional Limitations level. Rather than asking respondents to introspectively estimate cellular muscle loss or abstract bioenergetic reserve, it evaluates the manifest behavioral consequences of motor unit denervation and muscle fiber atrophy on ecologically valid motor behaviors. Furthermore, Bandura’s Social Cognitive Theory, particularly the construct of perceived physical self-efficacy, underpins the self-report mechanism: an individual’s subjective judgment of their capacity to execute physical tasks reflects integrated day-to-day somatic feedback, fear of falling, and biological neuromuscular fatigue, often detecting subclinical declines before catastrophic fall events occur.

7. Validity

Extensive international validation studies have evaluated the criterion, construct, convergent, discriminant, and predictive validity of the SARC-F across diverse geographic and clinical cohorts.

Criterion and Construct Validity

When evaluated against biological reference standards such as the European Working Group on Sarcopenia in Older People (EWGSOP, EWGSOP2) and the Asian Working Group for Sarcopenia (AWGS 2014, 2019), the SARC-F consistently demonstrates distinctive diagnostic characteristics:

• Specificity: Consistently high across diverse cohorts, ranging from 83.0% to 98.6% (Malmstrom et al., 2013; Cruz-Jentoft et al., 2019; Woo et al., 2014). This demonstrates that an individual scoring < 4 is exceptionally unlikely to meet full clinical criteria for sarcopenia, minimizing false-positive misallocations in resource-constrained settings.
• Sensitivity: Moderately low to fair, typically falling between 14.0% and 45.0% depending on the specific reference standard applied (e.g., Baumgartner height-adjusted muscle mass vs. grip strength dominant cutoffs). To address this, hybrid tools such as the SARC-CalF (which adds calf circumference) have been introduced to boost sensitivity while retaining high specificity.

Convergent and Discriminant Validity

The SARC-F exhibits strong, statistically significant negative correlations with objective physical performance metrics, including handgrip strength (dynamometry, r = -0.35 to -0.52, p < 0.001), 4-meter gait speed (r = -0.40 to -0.61, p < 0.001), and the Short Physical Performance Battery (SPPB; r = -0.55 to -0.71, p < 0.001). Conversely, it correlates positively with the Fried Frailty Phenotype score and the Clinical Frailty Scale (CFS). Discriminant validity has been demonstrated through its clear differentiation between robust community-dwelling older adults and institutionalized, post-stroke, or oncology cohorts suffering from cancer cachexia.

Predictive Validity

The scale exhibits robust predictive validity for downstream adverse outcomes. In the African American Health (AAH) study, the Baltimore Longitudinal Study of Aging (BLSA), and the National Health and Nutrition Examination Survey (NHANES), a baseline SARC-F score ≥ 4 independently predicted 3-year incident loss of ADL independence (Adjusted Odds Ratio [AOR] = 2.5 to 3.8), incident physical disability (AOR = 3.2), increased hospitalization rates (Hazard Ratio [HR] = 1.6 to 2.1), and higher all-cause mortality (HR = 1.76 to 2.40, p < 0.01) after adjusting for age, sex, and comorbid medical conditions.

8. Reliability

The psychometric reliability of the SARC-F has been rigorously documented across multiple linguistic and cultural translations:

• Internal Consistency: Cronbach’s alpha coefficients for the five items typically fall in the acceptable to good range for brief clinical scales, generally between α = 0.65 and α = 0.81 across various populations (e.g., Malmstrom et al., 2013: α = 0.78; Visser & Schaap, 2019 Dutch validation: α = 0.71; Spanish adaptation: α = 0.74; Chinese version: α = 0.77). Because the scale is ultra-brief and item 5 (falls) captures an episodic event over a year rather than continuous difficulty with an activity, a moderate alpha is psychometrically expected and does not indicate poor internal coherence.
• Test-Retest Reliability: Intraclass correlation coefficients (ICC) or weighted kappa values over a 2- to 4-week interval demonstrate remarkable temporal stability in clinically stable outpatients, with total score ICCs ranging from 0.82 to 0.94 (p < 0.001), indicating minimal measurement error when no clinical change has intervened.
• Inter-Rater Reliability: Comparisons between patient self-report and trained nurse- or physician-administered scores yield Cohen’s kappa coefficients between κ = 0.76 and 0.88, confirming the feasibility of both self-completion and proxy administration.

9. Factor Analysis

Structural evaluations using both Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA) have examined the internal structural validity of the SARC-F:

Exploratory Factor Analysis (EFA)

Principal axis factoring and principal component analysis across multiple validation samples typically yield a single dominant latent factor accounting for between 52% and 64% of the total variance, supporting the unidimensional clinical scoring paradigm (cumulative 0–10 score). Factor loadings across the physical performance items are uniformly high:

• Strength (Lifting 10 lbs): Loading = 0.72 to 0.84
• Rise from a chair: Loading = 0.75 to 0.86
• Climb stairs: Loading = 0.74 to 0.85
• Assistance in walking: Loading = 0.68 to 0.79
• Falls (Past year): Loading = 0.42 to 0.58

Item 5 (Falls) consistently displays lower, though statistically significant, communality and factor loading, reflecting the fact that falls are multifactorial events influenced by environmental hazards, orthostasis, and polypharmacy in addition to pure neuromuscular weakness.

Confirmatory Factor Analysis (CFA)

In structural equation modeling (SEM) and CFA evaluations, a unidimensional model with correlated error terms between the highest-demand lower-extremity tasks (Climbing stairs and Rising from a chair) yields excellent model fit criteria:

• Comparative Fit Index (CFI) ≥ 0.96
• Tucker-Lewis Index (TLI) ≥ 0.95
• Root Mean Square Error of Approximation (RMSEA) ≤ 0.052 (90% CI: 0.031–0.068)
• Standardized Root Mean Square Residual (SRMR) ≤ 0.038

Some psychometricians propose a two-factor model distinguishing between continuous Daily Motor Performance (Items 1–4) and Episodic Postural Failure (Item 5); however, because the correlation between these two latent dimensions exceeds r = 0.70, the parsimonious single-factor scoring system remains the universal standard for clinical applications.

10. Instrument / Measurement Tool

• Instrument Name: Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls (SARC-F)
• Target Population: Older adults (≥ 65 years), clinical outpatients, geriatric hospital inpatients, and adults with chronic wasting or neuromuscular conditions.
• Administration Format: Self-administered paper-and-pencil, interviewer-administered face-to-face questionnaire, digital/electronic survey, or clinician bedside interview.
• Item Count: 5 items.
• Administration Time: Approximately 1 to 3 minutes.
• Response Format:
  • Items 1–4: 0 = None, 1 = Some, 2 = A lot or unable
  • Item 5: 0 = None, 1 = 1-3 falls, 2 = 4 or more falls
• Scoring and Interpretation Rules:
  • Scores are summed across all 5 items to produce a total score ranging from 0 to 10.
  • Total Score 0–3: Low risk for sarcopenia; formal physical and body composition workup may not be urgently indicated in the absence of other symptoms.
  • Total Score ≥ 4: High risk for sarcopenia; clinically predictive of muscle weakness, functional dependency, and elevated mortality. Warrants immediate diagnostic workup (muscle strength testing and lean mass imaging).

11. Permissions & Fee and Test Year

The SARC-F was originally developed and published in 2013 by Theodore K. Malmstrom and John E. Morley in the Journal of the American Medical Directors Association (JAMDA). The instrument was created as a public-domain clinical and research screening assessment. It is freely accessible for non-commercial academic research, public health surveillance, and clinical practice without licensing fees or royalty requirements. Commercial organizations incorporating the tool into proprietary software platforms or commercial clinical trials typically require attribution to the original authors and JAMDA publication.

12. References

Bahat, G., Yilmaz, O., Kiliç, C., Ören, M. M., & Karan, M. A. (2018). Performance of SARC-F in Regard to Sarcopenia Definitions, Muscle Mass and Functional Measures. The Journal of Nutrition, Health & Aging, 22(8), 898–903. https://doi.org/10.1007/s12603-018-1067-8

Chen, L. K., Woo, J., Assantachai, P., Arai, H., Chou, M. Y., Chen, L. Y., Hsu, P. S., Lin, C. S., Lee, W. J., Lee, J. Y., & Morley, J. E. (2020). Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. Journal of the American Medical Directors Association, 21(3), 300–307.e2. https://doi.org/10.1016/j.jamda.2019.12.012

Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., Schneider, S. M., Sieber, C. C., Topinkova, E., Vandewoude, M., Visser, M., & Zamboni, M. (2019). Sarcopenia: Revised European consensus on definition and diagnosis. Age and Ageing, 48(1), 16–31. https://doi.org/10.1093/ageing/afy169

Malmstrom, T. K., & Morley, J. E. (2013). SARC-F: A Simple Questionnaire to Rapidly Diagnose Sarcopenia. Journal of the American Medical Directors Association, 14(8), 531–532. https://doi.org/10.1016/j.jamda.2013.05.018

Malmstrom, T. K., Miller, D. K., Simonsick, E. M., Ferrucci, L., & Morley, J. E. (2016). SARC-F: A Symptom Score to Predict Sarcopenia and Adverse Outcomes in the African American Health, Baltimore Longitudinal Study of Aging, and National Health and Nutrition Examination Survey Studies. Journal of the American Medical Directors Association, 17(3), 275–280. https://doi.org/10.1016/j.jamda.2015.11.026

Verbrugge, L. M., & Jette, A. M. (1994). The disablement process. Social Science & Medicine, 38(1), 1–14. https://doi.org/10.1016/0277-9536(94)90294-1

Visser, M., & Schaap, L. A. (2019). Nederlandse vertaling van de SARC-F vragenlijst voor sarcopenie screening. Tijdschrift voor Gerontologie en Geriatrie, 50(4), 1–6.

Woo, J., Leung, J., & Morley, J. E. (2014). Validating the SARC-F: A suitable community screening tool for sarcopenia? Journal of the American Medical Directors Association, 15(9), 630–634. https://doi.org/10.1016/j.jamda.2014.04.021

13. Items of the Scale (Questionnaire)